Corral-Blanco M, Prudencio-Ribera V C, Jarrín-Estupiñán M E, Alonso-Moralejo R, Pérez-González V, Meneses-Pardo J C, Hermira-Anchuelo A, De Pablo-Gafas A
Lung Transplantation Unit, 12 de Octubre University Hospital, Madrid, Spain.
Lung Transplantation Unit, 12 de Octubre University Hospital, Madrid, Spain.
Transplant Proc. 2019 Mar;51(2):380-382. doi: 10.1016/j.transproceed.2018.10.018. Epub 2018 Oct 28.
Pulmonary hypertension (PH) is a comorbidity associated with interstitial lung disease (ILD). The purpose of this study was to evaluate the influence of PH on intrahospital mortality in lung transplantation (LT) for ILD.
We conducted a retrospective cohort study of 66 patients who underwent LT for ILD at the 12 de Octubre University Hospital (Madrid, Spain) from October 2008 to June 2014. PH was defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg on right-sided heart catheterization and intrahospital mortality as any death taken place after the transplantation of patients not being discharged.
We retrospectively analyzed data of 66 patients; they were stratified by the presence or absence of PH before LT. Twenty-seven patients (41%) had PH. The PH group had a lower diffusing capacity of carbon monoxide (DLCO), carbon monoxide transfer coefficient (KCO), and 6-minute walk distance test (6MWT) and a higher total lung capacity (TLC), modified medical research council dyspnea scale (mMRC), and lung allocation score (LAS) than the non-PH group. Patients with PH more often underwent double lung transplantation (DLT; 59%) than single lung transplantation (SLT). Intrahospital mortality was 13% (9/66). No significant differences were observed in Kaplan-Meier survival curves for the PH and non-PH groups with a median survival time of 46 days versus 33 days (IQR 26-74; log-rank P = .056); however, the postoperative length of stay in the hospital was greater in the PH group.
In our cohort, pulmonary hypertension was not related to early mortality in lung transplantation recipients for interstitial lung diseases.
肺动脉高压（PH）是一种与间质性肺疾病（ILD）相关的合并症。本研究的目的是评估PH对ILD患者肺移植（LT）院内死亡率的影响。
我们对2008年10月至2014年6月在西班牙马德里12 de Octubre大学医院接受ILD-LT的66例患者进行了一项回顾性队列研究。PH定义为右侧心导管检查时平均肺动脉压（mPAP）≥25 mmHg，院内死亡率定义为移植后未出院患者发生的任何死亡。
我们回顾性分析了66例患者的数据；根据LT前是否存在PH对他们进行分层。27例患者（41%）患有PH。与非PH组相比，PH组一氧化碳弥散量（DLCO）、一氧化碳转移系数（KCO）和6分钟步行距离试验（6MWT）较低，而肺总量（TLC）、改良医学研究委员会呼吸困难量表（mMRC）和肺分配评分（LAS）较高。与单肺移植（SLT）相比，PH患者更常接受双肺移植（DLT；59%）。院内死亡率为13%（9/66）。PH组和非PH组的Kaplan-Meier生存曲线无显著差异，中位生存时间分别为46天和33天（IQR 26-74；对数秩P = 0.056）；然而，PH组术后住院时间更长。
在我们的队列中，肺动脉高压与间质性肺疾病肺移植受者的早期死亡率无关。
